CAR-T therapies

NHS England has announced a landmark deal, giving children and young people access to Novartis’ Kymriah (a chimeric antigen receptor T-cell, CAR-T, therapy) — a personalised therapy for the treatment of cancer. Read more


A Master Service Agreement has been entered by TxCell and Lonza Pharma & Biotech for the manufacture of a CAR-Treg cellular product (TX200), which is in development for the prevention of chronic rejection after organ transplantation. Read more


Swiss-based healthcare company, Novartis, has revealed that the US Food and Drug Administration (FDA) has approved its CAR-T therapy, Kymriah, for its second distinct indication. Read more


Data and analytics company, GlobalData, has released its findings from its review of the biopharmaceutical industry from 2017. Read more


Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. Read more


In this article, Frances Salisbury (partner) and Adam Gregory (associate) — European Patent Attorneys in the Life Sciences team at Mewburn Ellis — discuss innovation and IP of CAR-T therapies in more detail. Read more

, Opinion